Last $180.64 USD
Change Today +4.33 / 2.46%
Volume 1.9M
ILMN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 8:10 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILMN) Snapshot

Open
$177.82
Previous Close
$176.31
Day High
$180.74
Day Low
$175.81
52 Week High
07/2/14 - $184.49
52 Week Low
10/9/13 - $72.77
Market Cap
23.2B
Average Volume 10 Days
1.2M
EPS TTM
$1.58
Shares Outstanding
128.4M
EX-Date
--
P/E TM
114.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILMN)

illumina inc (ILMN) Details

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology are designed to meet the various demands of a range of sequencing applications; and array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of array-based genetic analysis products. It also offers various sample preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping and whole genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

3,000 Employees
Last Reported Date: 02/18/14
Founded in 1998

illumina inc (ILMN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $449.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILMN) Key Developments

Illumina Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 29, 2014; Revised Earnings Guidance for the Year 2014

Illumina Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 29, 2014. For the quarter, the company reported total revenue was $447,568,000 compared to $346,094,000 for the same period a year ago. Income from operations was $100,239,000 compared to $60,006,000 for the same period a year ago. Income before income taxes was $60,466,000 compared to $49,360,000 for the same period a year ago. Net income was $46,605,000 compared to $35,877,000 for the same period a year ago. Net income per diluted share was $0.31 compared to $0.26 for the same period a year ago. Net cash provided by operating activities was $178,030,000 compared to $88,606,000 for the same period a year ago. Purchases of property and equipment were $23,324,000 compared to $11,534,000 for the same period a year ago. Non-GAAP net income per diluted share was $0.57 compared to $0.43 for the same period a year ago. Non-GAAP net income was $84,570,000 compared to $59,694,000 for the same period a year ago. Non-GAAP operating profit was $155,722,000 compared to $111,663,000 for the same period a year ago. For the six months, the company reported was total revenue was $868,349,000 compared to $677,052,000 for the same period a year ago. Income from operations was $192,335,000 compared to $14,859,000 for the same period a year ago. Income before income taxes was $144,254,000 compared to $1,798,000 for the same period a year ago. Net income was $106,582,000 compared to $13,290,000 for the same period a year ago. Net income per diluted share was $0.71 compared to $0.10 for the same period a year ago. Net cash provided by operating activities was $215,117,000 compared to $176,446,000 for the same period a year ago. Purchases of property and equipment were $42,336,000 compared to $32,975,000 for the same period a year ago. Non-GAAP net income per diluted share was $1.10 compared to $0.90 for the same period a year ago. Non-GAAP net income was $164,617,000 compared to $122,313,000 for the same period a year ago. Non-GAAP operating profit was $302,701,000 compared to $221,726,000 for the same period a year ago. As a result of strong first half results, the company has increased its full year 2014 guidance to 25% to 26% revenue growth, and its non-GAAP earnings per fully diluted share to $2.26 to $2.28, higher than prior guidance of $2.10 to $2.15. Amortization of acquired intangible assets expected to be $0.20 per diluted share, non-cash interest expense per diluted share expected to be $0.16 and GAAP diluted net income per share in the range of $1.65 to $1.67. Additional modeling considerations include full year weighted average non-GAAP diluted share of $149 million, which assumes a stock price of $175; and a full year pro forma tax rate of 29%, which includes the 2014 federal R&D tax credit that has yet to be enacted. If the tax credit and other tax extend as in the past, annual tax rate would increase by approximately 200 basis points.

Berry Genomics and Illumina Co-Develop Integrated Next-Generation Sequencing System for Review and Approval by Chinese Regulatory Agency

Berry Genomics Co. Ltd. announced it has chosen Illumina Inc's. next-generation sequencing (NGS) technology as the platform on which Berry will secure Chinese Food and Drug Administration (CFDA) regulatory approval for clinical applications, thereby expanding access to NGS-based tests in China. Under the agreement, the companies co-developed an NGS system to provide a cost-effective, easy-to-use assay for non-invasive prenatal testing (NIPT). A working version of the new assay and instrument system has been validated in clinical settings in China, and is in late stage review under the CFDA's medical device registration process. The new system integrates Berry Genomics' Bambni(TM) assay, which includes a library preparation kit, analysis software, and a sequencing instrument based on Illumina's NextSeq(TM) 500 Sequencing System. Berry's proprietary Bambni(TM) assay, which has been validated on more than 200,000 samples, utilizes a unique PCR-free library prep technology and the proprietary RUPA(TM) analysis software.

Illumina Inc. Appoints Tina S. Nova as Senior Vice President and General Manager of its Oncology Business

Illumina Inc. announced that Tina S. Nova, Ph.D. has been named Senior Vice President and General Manager of Illumina's oncology business. Nova will lead the company's strategy for enabling the oncology community to develop innovative products across the full spectrum of cancer management based on Illumina next-generation sequencing technologies. Dr. Rick Klausner, who has served as interim oncology leader since January 2014, will continue in his role as Illumina's Senior Vice President and Chief Medical Officer. Previously, Nova co-founded the molecular diagnostics company Genoptix and served as its President and Chief Executive Officer from 2000. She was a member of the Genoptix board of directors until Novartis AG acquired the company in 2011. Nova also co-founded Nanogen Inc., where she was Chief Operating Officer and President from 1994 to 2000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILMN:US $180.64 USD +4.33

ILMN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $57.47 USD -0.25
Avago Technologies Ltd $73.63 USD -1.76
Becton Dickinson and Co $118.61 USD +0.37
QIAGEN NV €18.60 EUR +0.085
Waters Corp $104.79 USD -2.37
View Industry Companies
 

Industry Analysis

ILMN

Industry Average

Valuation ILMN Industry Range
Price/Earnings 100.0x
Price/Sales 15.0x
Price/Book 14.4x
Price/Cash Flow 92.6x
TEV/Sales 13.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.